STUDY OF OBLIMERSEN (GENASENSETM, G3139) IN ADVANCED MALIGNANCIES

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。该方案的总体目标是开发一种新的癌症治疗方法，将细胞毒性化疗与一种新的细胞凋亡抑制物相结合。这项研究的理由有几个方面。细胞毒剂吉西他滨对几种癌症有很强的抗癌活性。Oblimersen是bcl-2的反义抑制剂，已被证明作为单一药物在某些人类肿瘤中产生生长抑制和收缩。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The overall goal of this protocol is to develop a novel therapy for cancer, by combining a cytotoxic chemotherapy combination with a new inhibitor of apoptosis. The rationale for the study is several fold. The cytotoxic agent Gemcitabine has substantial activity against several cancers. Oblimersen is an antisense inhibitor of bcl-2 and has been shown to produce growth inhibition and shrinkage in some human tumors as a single agent.